Adaptimmune's ADP-A2M4 nabs RMAT tag for rare soft tissue cancer

• The FDA designates Adaptimmune Therapeutics' (ADAP +0.8%) T-cell therapy ADP-A2M4 a Regenerative Medicine Advanced Therapy (RMAT) for the treatment of synovial sarcoma, a rare type of soft tissue cancer, also an Orphan Drug indication in the U.S.
• RMAT, akin to Breakthrough Therapy status for drugs/biologics, provides for the accelerated review of the marketing application and more intensive guidance on development.